Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Colorectal cancer (CRC) prognosis is poor due to tumor recurrence and drug resistance.
• DNA mismatch repair (MMR) deficiency and elevated Interleukin-8 (IL-8) are linked to treatment resistance in CRC.
• Reduced MLH1 and SPTAN1 expression in CRC cells is associated with impaired therapeutic response and increased IL-8 release.

Purpose of the Study:

• To investigate the correlation between MLH1, SPTAN1 expression, and IL-8 levels in colorectal cancer.
• To explore the role of the RAS-mediated RAF/MEK/ERK pathway in CRC cells with reduced SPTAN1 expression.
• To evaluate the potential of combining ERK inhibition with FOLFOX chemotherapy.

Main Methods:

• Correlation analysis of intratumoral MLH1 and SPTAN1 expression with serum IL-8 levels in CRC patients.
• In vitro study using CRC cell lines (SW480, SW620, HT-29) with stably reduced SPTAN1 expression.
• Analysis of the RAF/MEK/ERK pathway, IL-8 secretion, and mesenchymal phenotype.
• Inhibition of ERK using U0126 and combination therapy with FOLFOX.

Main Results:

• Decreased intratumoral MLH1 and SPTAN1 expression significantly correlated with elevated serum IL-8.
• Low SPTAN1 expression was linked to increased IL-8 secretion, enhanced ERK phosphorylation, and a mesenchymal phenotype.
• ERK inhibition with U0126 significantly reduced IL-8 secretion.
• Combination therapy of U0126 and FOLFOX improved the response of CRC cell lines.

Conclusions:

• A connection exists between low MLH1/SPTAN1, high IL-8, and ERK pathway activation in CRC.
• Targeting the ERK pathway with U0126 can reduce IL-8 secretion.
• Combination therapy of FOLFOX and U0126 shows potential for improving treatment efficacy in a specific subgroup of CRCs.